Skip to main content

GRANZIMAS EN LA FISIOPATOLOGIA DE LA SEPSIS VIRAL Y BACTERIANA: PAPEL EN LA INFLAMACION AGUDA Y EN LA PARALISIS INMUNE E INFECCIONES SECUNDARIAS

PID2020-113963RB-I00

•
Funding agency name Agencia Estatal de Investigación
Funding agency acronym AEI
Program Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Call Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Call year 2020
State Plan 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Beneficiary centre UNIVERSIDAD DE ZARAGOZA

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Inflammatory cell death induced by cytotoxic lymphocytes: a dangerous but necessary liaison

  • Miguel, Diego de
  • Ramírez-Labrada, Ariel
  • Uranga Murillo, Iratxe
  • Hidalgo, Sandra
  • Santiago, Llipsy
  • Gálvez Buerba, Eva Mª
  • Arias, Maykel
  • Pardo, Julián
2 figures., Cytotoxic lymphocytes (CLs), and more specifically Tc and NK cells, are the main executors of cell death in the immune system, playing a key role during both immunosurveillance and immunotherapy. These cells induce regulated cell death (RCD) by different mechanisms, being granular exocytosis and expression of death ligands the most prominent and best characterized ones. Apoptosis, a traditionally considered low-inflammatory type of cell death, has been accepted for years as the paradigm of RCD induced by CLs. However, several recent studies have demonstrated that NK cells and Tc cells can also induce more inflammatory forms of cell death, namely, necroptosis, pyroptosis, and ferroptosis. Activation of these highly inflammatory types of cell death appears to critically contribute to the activation of a successful antitumour immune response. Additionally, the role of specific cell death pathways in immunogenic cell death is still under intense debate, especially considering the interconnections with other inflammatory forms of cell death. These evidences, together with the advent of new cancer immunotherapies, highlight the necessity to deepen our understanding of the link between the cell death triggered by CLs and inflammation. This knowledge will be instrumental to maximize the antitumour potential of immunotherapies, minimizing deleterious effects associated with these treatments. In this review, we will briefly summarize the main features of apoptosis, necroptosis, pyroptosis and ferroptosis, to subsequently discuss the most recent evidences about the role of these RCD pathways during the elimination of cancer cells mediated by CLs and its modulation to increase the efficacy of cancer immunotherapy., Work in the JP laboratory is funded by the FEDER (Fondo Europeo de Desarrollo Regional, Gobierno de Aragón, Group B29_17R), Ministerio de Ciencia, Innovación e Universidades (MCNU), Health National Institute Carlos III, Agencia Estatal de Investigación (SAF2017-83120-C2-1-R; PID2020-113963RB-I00), Fundación Inocente Inocente, ASPANOA and Carrera de la Mujer de Monzón. EMG is funded by Agencia Estatal de Investigación (SAF2017-83120-C2-1-R and PID2020-113963RB-I00). DDM is supported by a postdoctoral fellowship ‘Sara Borrell’, LS by a PhD fellowship (FPI) from the Ministry of Science, Innovation and Universities. IUM and SH are supported by a PhD fellowship from Aragon Government. MA is supported by a postdoctoral fellowship ‘Juan de la Cierva-formación’ from the Ministry of Science, Innovation and Universities, and JP is supported by the ARAID Foundation., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

CAR Immunotherapy for the treatment of infectious diseases: a systematic review

  • Morte Romea, Elena
  • Pesini, Cecilia
  • Pellejero, Galadriel
  • Martínez-Lostao, Luis
  • Loscos, Silvia
  • Toyas, Carla
  • Redrado, Sergio
  • Dolader, Elena
  • Arias, Maykel
  • Gálvez Buerba, Eva Mª
  • Sanz-Pamplona, Rebeca
  • Pardo, Julián
  • Paño, José Ramón
  • Ramírez-Labrada, Ariel
4 figures.-- Supplementary information available., Immunotherapy treatments aim to modulate the host’s immune response to either mitigate it in inflammatory/autoimmune disease or enhance it against infection or cancer. Among different immunotherapies reaching clinical application during the last years, chimeric antigen receptor (CAR) immunotherapy has emerged as an effective treatment for cancer where different CAR T cells have already been approved. Yet their use against infectious diseases is an area still relatively poorly explored, albeit with tremendous potential for research and clinical application. Infectious diseases represent a global health challenge, with the escalating threat of antimicrobial resistance underscoring the need for alternative therapeutic approaches. This review aims to systematically evaluate the current applications of CAR immunotherapy in infectious diseases and discuss its potential for future applications. Notably, CAR cell therapies, initially developed for cancer treatment, are gaining recognition as potential remedies for infectious diseases. The review sheds light on significant progress in CAR T cell therapy directed at viral and opportunistic fungal infections., The author(s) declare financial support was received for the research, authorship, and/or publication of this article. Work in the JP laboratory is funded by CIBER -Consorcio Centro de Investigación Biomédica en Red-(CB21/13/00087), Instituto de Salud Carlos III, FEDER (Fondo Europeo de Desarrollo Regional), Gobierno de Aragón (Group B29_23R, and LMP139_21), Grant PID2020-113963RB-I00 by MCIN/AEI/10.13039/501100011033, ASPANOA, and Carrera de la Mujer de Monzón. Contrato Ramon y Cajal RYC2022-036627-I (AR-L), Postdoctoral Juan de la Cierva Contract (MA and LS), Predoctoral Grant for Ibero-Americas in Doctoral studies University of Zaragoza-Santander University (ACP), and Predoctoral Grant from AECC (CP). Fundación Científica Asociación Española Contra el Cáncer (AECC) (CP), Río Hortega contrat, Instituto de Salud Carlos III, Post physician specialization, Instituto de Investigación Sanitaria IIS Aragón., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

In-depth analysis of the interplay between oncogenic mutations and NK cell-mediated cancer surveillance in solid tumors

  • Pesini, Cecilia
  • Artal Cortés, Laura
  • Paúl Bernal, Jorge
  • Sánchez Martínez, Diego
  • Ramírez-Labrada, Ariel
3 figures, 1 table., Natural killer (NK) cells play a crucial role in antitumoral and antiviral responses. Yet, cancer cells can alter themselves or the microenvironment through the secretion of cytokines or other factors, hindering NK cell activation and promoting a less cytotoxic phenotype. These resistance mechanisms, often referred to as the “hallmarks of cancer” are significantly influenced by the activation of oncogenes, impacting most, if not all, of the described hallmarks. Along with oncogenes, other types of genes, the tumor suppressor genes are frequently mutated or modified during cancer. Traditionally, these genes have been associated with uncontrollable tumor growth and apoptosis resistance. Recent evidence suggests oncogenic mutations extend beyond modulating cell death/proliferation programs, influencing cancer immunosurveillance. While T cells have been more studied, the results obtained highlight NK cells as emerging key protagonists for enhancing tumor cell elimination by modulating oncogenic activity. A few recent studies highlight the crucial role of oncogenic mutations in NK cell-mediated cancer recognition, impacting angiogenesis, stress ligands, and signaling balance within the tumor microenvironment. This review will critically examine recent discoveries correlating oncogenic mutations to NK cell-mediated cancer immunosurveillance, a relatively underexplored area, particularly in the era dominated by immune checkpoint inhibitors and CAR-T cells. Building on these insights, we will explore opportunities to improve NK cell-based immunotherapies, which are increasingly recognized as promising alternatives for treating low-antigenic tumors, offering significant advantages in terms of safety and manufacturing suitability., Work in the laboratory is funded by CIBER -Consorcio Centro de Investigación Biomédica en Red- (CB21/13/00087), Instituto de Salud Carlos III, FEDER (Fondo Europeo de Desarrollo Regional), Gobierno de Aragón (Group B29_23R), Ministerio de Ciencia, Innovación e Universidades (MICIU); and Agencia Estatal de Investigación (PID2020-113963RB-I00), ASPANOA, and Carrera de la Mujer de Monzón. DSM received funding from “Grant PID2022-136554OA-I00 funded by MICIU/AEI/10.13039/501100011033 and by “ERDF/EU”. Contrato Ramón y Cajal RYC2022-036627-I (AR-L), Predoctoral Grant from Fundación Científica Asociación Española Contra el Cáncer (CP) and Becas de introducción a la investigación JAEICU_24_00214 (LA)., Peer reviewed